Clinical Trial: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Plaque Psoriasis
Study Type: INTERVENTIONAL
Official Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability
Brief Summary:
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo).Participants will be in the study for up to 69 weeks.
Read more